We would love to hear your thoughts about our site and services, please take our survey here.
"how can price sensitive data be withheld from Shareholders until the opportunity arises such as AACR or ASCO, where 'previously unpublished data' is a requirement"
My guess - and it is only a guess - is that "published" means in a professional medical paper, rather than an RNS.
While you are factually correct, Ruck, IMO there is no reason the RNS cannot be both regulatory info and a marketing opportunity. If it was strictly regulatory compliance it would not have been relevant to use the phrase "exceptional results".
Think he sold up completely a few months ago, Troaj. And, unlike some (not yourself!) is respectful enough not to continue posting here, and/or likely has more important things on his mond.
I notice you pay a fair bit of attention to SCLP news - do you have a holding here? I'm hoping this one will more than cover my losses on the disastrous Masterman mine.
Great pre-AGM news this morning. Does "complete response" mean what I think it does?
Thanks to all those who commented on the Texas Biomed reply. For the reasons others have given, I wasn't reading much into their involvement with Covidity but the dates of the recent published media warranted some explanation I felt. Still not sure that is fully answered but clearly it referenced earlier work, not ongoing.
With all the intrigue around the Texas Biomed media, I thought there was nothing to lose by just emailing them to ask if the Scancell-related work is current or not. Happily, I just got the following reply from Heidi Meisenkothen, Director, Business Development and Strategic Alliances Applied Science and Innovation ...
"We appreciate your interest in Texas Biomed.
This work has successfully been completed ā please refer to publication:
https://www.fortunejournals.com/articles/sarscov2-spike-rbd-and-nucleocapsid-encoding-dna-vaccine-elicits-t-cell-and-neutralising-antibody-responses-that-cross-react-with-.html
Thank you."
I've not had a chance to read the publication yet, but the usual clever people in here might find it informative.
Https://www.bbc.co.uk/news/business-67087678
"Social media is now full of big-name short sellers and amateur traders loudly pointing out what stocks they think are destined to fall."
No loud amateurs on here, surely ???
I'd like to reiterate Douve's request for a link to Lindy's Q&A if there is one. Somewhere in that section I detected she just stopped herself saying "add something BETTER" when discussing the CPI's, and quickly changed it to "add something extra" (or something along those lines). Would love to hear it again to make sure.
Ruck "crackin called it right as it turned out" - no, he said we were going down to 5p, and after MacMillan-gate revised that down to 3p.
Anyway, don't want to get into personal spats, just enjoying this morning's ride.
I'm a bit late to the discussion, but to add to moonparty's comment on LD's statement that "The information extracted from this study will be invaluable in defining the patient population that will benefit the most from our cancer vaccine, Modi-1." ... I note she says "WILL benefit", not "MAY benefit" as has been the cautious tone previously. Hopefully I'm not reading too much into one word.
... authored by these people
https://uk.linkedin.com/in/stuartksims
https://vulpesinvest.com/teams/jamshed-dadabhoy/
I'm imagining that the doctor is the one who did Vulpes' original due diligance on the science side.